|
|
|
European Biopharmaceutical Review
|
<p align="justify" class="feature">The term 'amyloid' was introduced in scientific literature in the mid-19th Century to describe macroscopic abnormalities in organs and tissues of patients afflicted with a variety of clinical syndromes. It took almost a century to realise that these amyloid deposits consisted of fibrillar ultrastructures when examined by electron microscopy (see Figure 1).
Subsequently, numerous studies followed which confirmed that deposits of diverse origin show a similar, fibrillar submicroscopic structure consisting of bundles of straight and rigid fibrils. Several amyloid disorders have since been discovered. Although diverse in etiology and pathogenesis, they all demonstrate this accumulation of large fibrillary protein aggregates which interfere with specificorgan functions.
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
PHASE II & IIa Clinical Trials
21-22 February 2012, Lancaster London Hotel, London
Learn how to overcome challenges in adapting the development process to achieve early Proof of Concept at Informa's 13th Annual Phase I & IIa Clinical Trials event.
More info >> |
|
 |
News and Press Releases |
 |
The Marketing Machine Helps International Pharma Client with Ambitious Literacy Drug Packaging Rebrand
Full-service advertising and branding firm The Marketing Machine recently finished an ambitious, innovative rebranding project for Danadams Pharmaceuticals Industry Limited to help overcome literacy and distribution challenges with patients in Ghana, South Africa. The firm utilized its award-winning design services team to redesign all of Danadams branding and packaging using intuitive visual icons and color elements to indicate the type of drugs and dosages and better display information more clearly and legibly. Danadams Pharmaceuticals is currently the only manufacturer of anti-retroviral drugs in West Africa. It also manufactures and sells anti-malarials, antibiotics, analgesics and other opportunistic infection drugs for the West African market.
More info >> |
|
|
